Breast Cancer: Page 3

PathomIQ presents data on AI predictive model at SABCS

By LabPulse.com staff writers

The model predicts the response to neoadjuvant chemotherapy in patients with triple-negative breast cancer through extracting morphological features.

December 8, 2022

Exact Sciences to present study data on its precision oncology portfolio at SABCS

By LabPulse.com staff writers

The firm announced that it will be sharing the data in 10 abstracts and three presentations, highlighting its Oncotype Dx Breast Recurrence Score and Oncomap ExTra tests, as well as offering a look at its tumor-naïve MRD approach.

December 7, 2022

Agendia to present abstracts on gene expression profiling tests at 2022 San Antonio Breast Cancer Symposium

By LabPulse.com staff writers

Six studies focus on the impact of Agendia's MammaPrint and BluePrint tests and their ability to unveil the underlying biology of a breast cancer patient’s tumor to inform personalized treatment decisions.

December 6, 2022

At SABCS, University of Rochester professor presents clinical trial results for Biotheranostics Breast Cancer Index

By LabPulse.com staff writers

The Breast Cancer Index test is the first biomarker to be evaluated in a cohort from the Suppression of Ovarian Function Trial (SOFT), Hologic noted.

December 7, 2022

Reveal Genomics presents trial results for HER2Dx breast cancer test at SABCS

By LabPulse.com staff writers

The results show that an HER2Dx risk score was significantly associated with relapse-free interval and long-term survival outcomes; additionally, HER2Dx can identify patients who might be candidates for neoadjuvants or de-escalation of systemic therapy.

December 6, 2022

Myriad Genetics to present new data at San Antonio Breast Cancer Symposium

By LabPulse.com staff writers

A spotlight discussion will highlight how a combined risk score may lead to improved breast cancer prevention and screening strategies.

November 30, 2022

Halo Diagnostics, Ikonopedia partner to integrate genetic testing, breast cancer imaging software

By LabPulse.com staff writers

Halo Diagnostics announced a partnership with Ikonopedia that aims to improve the detection of breast cancer by integrating genetic testing with imaging.

November 28, 2022

Netherlands study finds blood protein level changes two years prior to breast cancer diagnosis

By Jared Berberabe

The study found that prior to being diagnosed with breast cancer, women may experience changes in the levels of certain proteins found in the bloodstream, leading to the potential for early detection using blood tests.

November 16, 2022

Delphi Diagnostics announces use of genetic test in ongoing breast cancer trial

By LabPulse.com staff writers

While the test has been used to assess tumors in the ongoing trial for the past year, it will now additionally be used for adaptive randomization of patients whose biomarker profiles show that they may benefit from endocrine therapy.

October 27, 2022

Prelude Dx to present clinical utility data for DCIS risk assessment test

By LabPulse.com staff writers

DCISionRT predicts radiation therapy benefit through a risk assessment test for patients with ductal carcinoma in situ (DCIS).

October 21, 2022

Boston Cell Standards nabs FDA clearance for IHC test panel to evaluate breast cancers

By LabPulse.com staff writers

Boston Cell Standards on Thursday announced that the FDA has granted 510(k) clearance for the company’s IHControls panel for evaluating breast cancers.

October 6, 2022

Roche gets FDA approval for metastatic breast cancer CDx

By LabPulse.com staff writers

The Pathway anti-HER2 (4B5) test is now FDA-approved for use in the assessment of metastatic breast cancer patients who may be eligible for Enhertu, an HER2-directed antibody drug conjugate.

October 4, 2022

Previous Page

Page 3 of 12

Next Page